Cargando…
Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely re...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977274/ https://www.ncbi.nlm.nih.gov/pubmed/31969174 http://dx.doi.org/10.1186/s13014-020-1470-2 |
_version_ | 1783490472734359552 |
---|---|
author | Stegen, Benjamin Nieto, Alexander Albrecht, Valerie Maas, Jessica Orth, Michael Neumaier, Klement Reinhardt, Sabine Weick-Kleemann, Moritz Goetz, Wilfried Reinhart, Merle Parodi, Katia Belka, Claus Niyazi, Maximilian Lauber, Kirsten |
author_facet | Stegen, Benjamin Nieto, Alexander Albrecht, Valerie Maas, Jessica Orth, Michael Neumaier, Klement Reinhardt, Sabine Weick-Kleemann, Moritz Goetz, Wilfried Reinhart, Merle Parodi, Katia Belka, Claus Niyazi, Maximilian Lauber, Kirsten |
author_sort | Stegen, Benjamin |
collection | PubMed |
description | BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely reflect the clinical situation. So far, image-guided, fractionated radiotherapy of orthotopic GBM models represents a major limitation in this regard. METHODS: GL261 mouse GBM cells were inoculated into the right hemispheres of C57BL/6 mice. Tumor growth was monitored by contrast-enhanced conebeam CT (CBCT) scans. When reaching an average volume of approximately 7 mm(3), GBM tumors were irradiated with daily fractions of 2 Gy up to a cumulative dose of 20 Gy in different beam collimation settings. For treatment planning and tumor volume follow-up, contrast-enhanced CBCT scans were performed twice per week. Daily repositioning of animals was achieved by alignment of bony structures in native CBCT scans. When showing neurological symptoms, mice were sacrificed by cardiac perfusion. Brains, livers, and kidneys were processed into histologic sections. Potential toxic effects of contrast agent administration were assessed by measurement of liver enzyme and creatinine serum levels and by histologic examination. RESULTS: Tumors were successfully visualized by contrast-enhanced CBCT scans with a detection limit of approximately 2 mm(3), and treatment planning could be performed. For daily repositioning of the animals, alignment of bony structures in native CT scans was well feasible. Fractionated irradiation caused a significant delay in tumor growth translating into significantly prolonged survival in clear dependence of the beam collimation setting and margin size. Brain sections revealed tumors of similar appearance and volume on the day of euthanasia. Importantly, the repeated contrast agent injections were well tolerated, as liver enzyme and creatinine serum levels were only subclinically elevated, and liver and kidney sections displayed normal histomorphology. CONCLUSIONS: Contrast-enhanced, CT-based, fractionated radiation of orthotopic mouse GBM represents a versatile preclinical technique for the development and evaluation of multimodal radiotherapeutic approaches in combination with novel therapeutic agents in order to accelerate translation into clinical testing. |
format | Online Article Text |
id | pubmed-6977274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69772742020-01-28 Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study Stegen, Benjamin Nieto, Alexander Albrecht, Valerie Maas, Jessica Orth, Michael Neumaier, Klement Reinhardt, Sabine Weick-Kleemann, Moritz Goetz, Wilfried Reinhart, Merle Parodi, Katia Belka, Claus Niyazi, Maximilian Lauber, Kirsten Radiat Oncol Research BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely reflect the clinical situation. So far, image-guided, fractionated radiotherapy of orthotopic GBM models represents a major limitation in this regard. METHODS: GL261 mouse GBM cells were inoculated into the right hemispheres of C57BL/6 mice. Tumor growth was monitored by contrast-enhanced conebeam CT (CBCT) scans. When reaching an average volume of approximately 7 mm(3), GBM tumors were irradiated with daily fractions of 2 Gy up to a cumulative dose of 20 Gy in different beam collimation settings. For treatment planning and tumor volume follow-up, contrast-enhanced CBCT scans were performed twice per week. Daily repositioning of animals was achieved by alignment of bony structures in native CBCT scans. When showing neurological symptoms, mice were sacrificed by cardiac perfusion. Brains, livers, and kidneys were processed into histologic sections. Potential toxic effects of contrast agent administration were assessed by measurement of liver enzyme and creatinine serum levels and by histologic examination. RESULTS: Tumors were successfully visualized by contrast-enhanced CBCT scans with a detection limit of approximately 2 mm(3), and treatment planning could be performed. For daily repositioning of the animals, alignment of bony structures in native CT scans was well feasible. Fractionated irradiation caused a significant delay in tumor growth translating into significantly prolonged survival in clear dependence of the beam collimation setting and margin size. Brain sections revealed tumors of similar appearance and volume on the day of euthanasia. Importantly, the repeated contrast agent injections were well tolerated, as liver enzyme and creatinine serum levels were only subclinically elevated, and liver and kidney sections displayed normal histomorphology. CONCLUSIONS: Contrast-enhanced, CT-based, fractionated radiation of orthotopic mouse GBM represents a versatile preclinical technique for the development and evaluation of multimodal radiotherapeutic approaches in combination with novel therapeutic agents in order to accelerate translation into clinical testing. BioMed Central 2020-01-22 /pmc/articles/PMC6977274/ /pubmed/31969174 http://dx.doi.org/10.1186/s13014-020-1470-2 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Stegen, Benjamin Nieto, Alexander Albrecht, Valerie Maas, Jessica Orth, Michael Neumaier, Klement Reinhardt, Sabine Weick-Kleemann, Moritz Goetz, Wilfried Reinhart, Merle Parodi, Katia Belka, Claus Niyazi, Maximilian Lauber, Kirsten Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
title | Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
title_full | Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
title_fullStr | Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
title_full_unstemmed | Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
title_short | Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
title_sort | contrast-enhanced, conebeam ct-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977274/ https://www.ncbi.nlm.nih.gov/pubmed/31969174 http://dx.doi.org/10.1186/s13014-020-1470-2 |
work_keys_str_mv | AT stegenbenjamin contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT nietoalexander contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT albrechtvalerie contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT maasjessica contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT orthmichael contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT neumaierklement contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT reinhardtsabine contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT weickkleemannmoritz contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT goetzwilfried contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT reinhartmerle contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT parodikatia contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT belkaclaus contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT niyazimaximilian contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy AT lauberkirsten contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy |